Black Diamond’s EFGR-targeted glioblastoma drug candidate slows tumor development in mice


Black Diamond Therapeutics was launched in 2018 with a objective of pursuing focused most cancers therapies from a wholly unique approach. As an alternative of drugging mutated genes that drive most cancers, Black Diamond got down to goal “allosteric mutations,” genetic abnormalities that might be selectively drugged via a portion of the kinase enzyme referred to as the ATP binding web site.

The corporate is utilizing the method to assault one of many hardest tumors to deal with, the mind most cancers glioblastoma—and now it has promising leads to mice for its chosen drug candidate.

The compound, referred to as BDTX-1535, inhibited tumor development in mouse fashions of glioblastoma with allosteric EGFR mutations, the corporate introduced in the course of the digital 2020 Society for Neuro-Oncology annual assembly.

About half of glioblastoma tumors have EGFR variants, defined Elizabeth Buck, Ph.D., government vice chairman of discovery and translational sciences, in the course of the presentation (PDF). BDTX-1535 was designed to have the ability to cross the blood-brain barrier and selectively goal allosteric EGFR mutations. Preclinical testing confirmed that the drug hit its goal with out affecting non-mutated types of EGFR—a possible security benefit, Buck mentioned.

RELATED: In a rush? A yr after exiting stealth mode, Black Diamond weapons for IPO

Different makes an attempt to focus on EGFR in glioblastoma have been made, with little success. Final yr, a trial of AbbVie’s antibody-drug conjugate depatuxizumab mafodotin in glioblastoma, for instance, was halted resulting from a scarcity of survival profit.

Analysis teams at a number of educational establishments are analyzing the potential for CAR-T cell therapies in glioblastoma, together with Massachusetts Normal Hospital, Metropolis of Hope and McMaster College with the College of Toronto.

Black Diamond, a 2019 Fierce 15 winner, refers to its method to concentrating on allosteric mutations as MasterKey due to the potential for a single drug candidate to assault households of oncogenic mutations throughout a number of tumor varieties. Glioblastoma is without doubt one of the tumor varieties that expresses a number of allosteric EGFR mutations. In cell research, BDTX-1535 inhibited all of them, main the corporate to decide on the drug over different candidates.

Black Diamond raised $105 million in its first two years of life after which staged an preliminary public providing in January of this yr that pulled in $201 million—twice its authentic objective. The corporate’s lead drug candidate, BDTX-189, is presently in section 1 trials for EGFR and HER2 mutations in strong tumors.

The corporate has launched further research of BDTX-1535 and hopes to use to the FDA for approval to launch scientific trials of the drug in glioblastoma within the first half of 2022.


Please enter your comment!
Please enter your name here